Literature DB >> 22665529

Optimizing investigator-led oncology research in Europe.

Tiziano Barbui, Magnus Björkholm, Alois Gratwohl.   

Abstract

Mesh：

Year:  2012        PMID： 22665529      PMCID： PMC3366643          DOI： 10.3324/haematol.2012.064873

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

Review 1.  Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Authors:  John W Park; Robert S Kerbel; Gary J Kelloff; J Carl Barrett; Bruce A Chabner; David R Parkinson; Jonathan Peck; Raymond W Ruddon; Caroline C Sigman; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

Review 2.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

3.  Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.

Authors:  David B Ridley; Alfonso Calles Sánchez
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

4.  Evidence of comparative efficacy should have a formal role in European drug approvals.

Authors:  Corinna Sorenson; Huseyin Naci; Jonathan Cylus; Elias Mossialos
Journal:  BMJ       Date:  2011-09-06

5.  End points in cancer clinical trials and the drug approval process.

Authors:  Richard L Schilsky
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

Review 6.  Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.

Authors:  C McCabe; L Bergmann; N Bosanquet; M Ellis; H Enzmann; M von Euler; B Jönsson; K-J Kallen; D Newling; V Nüssler; B Paschen; R de Wilde; N Wilking; C Teale; H Zwierzina
Journal:  Ann Oncol       Date:  2008-10-14       Impact factor: 32.976

7.  Trends in the global funding and activity of cancer research.

Authors:  Seth Eckhouse; Grant Lewison; Richard Sullivan
Journal:  Mol Oncol       Date:  2008-03-27       Impact factor: 6.603

8.  Methods for the comparative evaluation of pharmaceuticals.

Authors:  Annette Zentner; Marcial Velasco-Garrido; Reinhard Busse
Journal:  GMS Health Technol Assess       Date:  2005-11-15

9.  Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation.

Authors:  Alois Gratwohl; Ronald Brand; Dietger Niederwieser; Helen Baldomero; Christian Chabannon; Jan Cornelissen; Theo de Witte; Per Ljungman; Fiona McDonald; Eoin McGrath; Jakob Passweg; Christina Peters; Vanderson Rocha; Ineke Slaper-Cortenbach; Anna Sureda; Andre Tichelli; Jane Apperley
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

10.  Impact of the European clinical trials directive on prospective academic clinical trials associated with BMT.

Authors:  L J Frewer; D Coles; I A van der Lans; D Schroeder; K Champion; J F Apperley
Journal:  Bone Marrow Transplant       Date:  2010-06-07       Impact factor: 5.483
View more
  2 in total

1.  Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation.

Authors:  Alois Gratwohl; Ronald Brand; Eoin McGrath; Anja van Biezen; Anna Sureda; Per Ljungman; Helen Baldomero; Christian Chabannon; Jane Apperley
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

2.  Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013.

Authors:  Urs Brügger; Bruno Horisberger; Alexander Ruckstuhl; Rafael Plessow; Klaus Eichler; Alois Gratwohl
Journal:  BMJ Open       Date:  2015-03-27       Impact factor: 2.692
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.